Novo Nordisk vs. Eli Lilly: Wegovy Pill Performance and Stock Outlook in 2026 - News and Statistics

Jun 6, 2026

The pharmaceutical sector is defined by intense rivalry and a constant push for new treatments. This dynamic is clearly illustrated by the contest between Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in the emerging GLP-1 weight-loss market. Although Eli Lilly currently appears to have the upper hand, Novo Nordisk‘s oral version of Wegovy is exceeding initial expectations. This development could make the stock an attractive long-term option for investors seeking dividends.

Novo Nordisk’s Early Missteps

Novo Nordisk was the first company to bring a GLP-1 weight-loss medication to market. However, it struggled to manufacture enough of its Wegovy injection to satisfy demand. This shortfall allowed compounding pharmacies to enter the U.S. market, which limited Novo Nordisk’s potential for growth. It also created a significant opportunity for competitor Eli Lilly when it introduced its own GLP-1 treatments, Mounjaro and Zepbound.

Eli Lilly’s drugs also demonstrated greater effectiveness, leading to strong financial results for that company while Novo Nordisk worked to catch up. Investors responded by selling shares of Novo Nordisk and purchasing Eli Lilly. The performance gap has been substantial, with Novo Nordisk’s stock declining by 40% over the past three years, while Eli Lilly’s shares have risen by more than 150%.

A Turning Point in 2026

A significant shift occurred at the beginning of 2026, when Novo Nordisk launched a tablet form of Wegovy. Many patients prefer pills to injections, which broadens the potential customer base for GLP-1 drugs. This has been confirmed by the company’s experience, as the pill has achieved faster growth than the injectable version. Furthermore, the pill does not appear to be reducing sales of the injection, indicating that the overall GLP-1 market is expanding. The pill’s performance has surpassed the company’s own projections, generating 1.3 million prescriptions in the first quarter alone. One month later, when Novo Nordisk reported its first-quarter earnings, the prescription count had jumped to two million.

Challenges Ahead for Novo Nordisk

Despite this success, Novo Nordisk has cautioned investors that 2026 will be a difficult year. The company is losing patent protection for Wegovy in India, which is putting pressure on its sales in that large market. Additionally, Novo Nordisk has agreed to reduce prices in the U.S., which is also affecting its revenue. Management anticipates that higher sales volume will eventually compensate for lower prices, especially as the Wegovy pill attracts more patients to the GLP-1 category. Given the pill’s early performance, this scenario appears increasingly plausible.

Interactive table based on the Store Companies dataset for this report.

Sort: Rank
Sort: Company A-Z
Sort: Headquarters A-Z

#
Company
Headquarters
Focus
Scale
Note

1
Pfizer Inc.
New York, USA
Broad pharmaceuticals
Global leader
Original penicillin developer, major producer

2
GlaxoSmithKline plc
London, UK
Pharmaceuticals, vaccines
Global
Major antibiotics portfolio including penicillins

3
Novartis AG
Basel, Switzerland
Broad pharmaceuticals
Global
Produces penicillin derivatives via Sandoz

4
Merck & Co., Inc.
New Jersey, USA
Pharmaceuticals
Global
Key antibiotic manufacturer

5
AstraZeneca plc
Cambridge, UK
Pharmaceuticals
Global
Historically significant, still produces antibiotics

6
Sanofi
Paris, France
Pharmaceuticals
Global
Major producer of antibiotics

7
Roche Holding AG
Basel, Switzerland
Pharmaceuticals, diagnostics
Global
Produces antibiotic compounds

8
Bayer AG
Leverkusen, Germany
Pharmaceuticals, crop science
Global
Manufactures penicillin-based antibiotics

9
AbbVie Inc.
Illinois, USA
Biopharmaceuticals
Global
Includes legacy antibiotic products

10
Bristol Myers Squibb
New York, USA
Biopharmaceuticals
Global
Historically strong in anti-infectives

11
Johnson & Johnson
New Jersey, USA
Healthcare conglomerate
Global
Via Janssen, produces antibiotics

12
Teva Pharmaceutical Industries
Tel Aviv, Israel
Generics
Global
Major generic antibiotics producer

13
Viatris Inc.
Pennsylvania, USA
Generics, specialty
Global
Large portfolio of generic antibiotics

14
Sun Pharmaceutical Industries
Mumbai, India
Generics, specialty
Global
Major API and formulation producer

15
Dr. Reddy’s Laboratories
Hyderabad, India
Generics, APIs
Global
Key producer of antibiotic APIs

16
Cipla Ltd.
Mumbai, India
Generics
Global
Major antibiotics manufacturer

17
Lupin Limited
Mumbai, India
Generics
Global
Significant antibiotics portfolio

18
Aurobindo Pharma
Hyderabad, India
Generics, APIs
Global
Large-scale penicillin and derivative producer

19
Fresenius Kabi
Bad Homburg, Germany
Generics, infusion therapy
Global
Produces injectable antibiotics

20
Hikma Pharmaceuticals
London, UK
Generics, injectables
Global
Major injectable antibiotics supplier

21
Sandoz International GmbH
Basel, Switzerland
Generics, biosimilars
Global
World’s leading generic antibiotics company

22
STADA Arzneimittel AG
Bad Vilbel, Germany
Generics, consumer health
Europe
Significant antibiotics producer

23
Zhejiang Hisun Pharmaceutical
Taizhou, China
APIs, formulations
Global
Major Chinese API producer for antibiotics

24
North China Pharmaceutical Group
Shijiazhuang, China
APIs, antibiotics
Global
One of world’s largest penicillin producers

25
CSPC Pharmaceutical Group
Shijiazhuang, China
Pharmaceuticals, APIs
Global
Major antibiotics and vitamin C producer

26
Sinopharm Group
Beijing, China
Healthcare conglomerate
Global
Includes antibiotic manufacturing subsidiaries

27
Yuhan Corporation
Seoul, South Korea
Pharmaceuticals
Regional
Leading Korean antibiotic producer

28
Daiichi Sankyo Company
Tokyo, Japan
Pharmaceuticals
Global
Produces antibiotic agents

29
Takeda Pharmaceutical Company
Tokyo, Japan
Pharmaceuticals
Global
Includes legacy antibiotic products

30
ACS Dobfar S.p.A.
Tribiano, Italy
Antibiotic APIs
Global
Leading European penicillin API manufacturer

This report provides a comprehensive view of the global penicillins or streptomycins medicaments industry, tracking demand, supply, and trade flows across the worldwide value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between exporters and importers worldwide. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the global penicillins or streptomycins medicaments landscape.

Quick navigation
Key findings

Global demand is shaped by both household and industrial usage, with trade flows linking cost-competitive producers to import-reliant markets.
Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
Supply depends on input availability and production efficiency, creating distinct cost curves across regions.
Market concentration varies by country, creating different competitive landscapes and entry barriers.
The 2035 outlook highlights where capacity investment and demand growth are most aligned globally.
Report scope

The report combines market sizing with trade intelligence and price analytics. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts across countries and regions.

Market size and growth in value and volume terms
Consumption structure by end-use segments and regions
Production capacity, output, and cost dynamics
Global trade flows, exporters, importers, and balances
Price benchmarks, unit values, and margin signals
Competitive context and market entry conditions
Product coverageProdcom 21201160 – Medicaments of penicillins, streptomycins or derivatives thereof, in doses or p.r.s.Country coverageCountry profiles and benchmarks

For the global report, country profiles provide a consistent view of market size, trade balance, prices, and per-capita indicators. The profiles highlight the largest consuming and producing markets and allow direct benchmarking across peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

International trade data (exports, imports, and mirror statistics)
National production and consumption statistics
Company-level information from financial filings and public releases
Price series and unit value benchmarks
Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links penicillins or streptomycins medicaments demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts.

Historical baseline: 2012-2025
Forecast horizon: 2026-2035
Scenario-based sensitivity to income growth, substitution, and regulation
Capacity and investment outlook for major producing countries

Each country projection is built from its own historical pattern and the regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

Price benchmarks by country and sub-region
Export and import unit value trends
Seasonality and calendar effects in trade flows
Price outlook to 2035 under baseline assumptions
Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

Business focus and production capabilities
Geographic reach and distribution networks
Cost structure and pricing strategy indicators
Compliance, certification, and sustainability context
How to use this report

Quantify global demand and identify the most attractive markets
Evaluate export opportunities and prioritize target countries
Track price dynamics and protect margins
Benchmark performance against major competitors
Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of global penicillins or streptomycins medicaments dynamics.

FAQ
What is included in the global penicillins or streptomycins medicaments market?

The market size aggregates consumption and trade data at country and regional levels, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which countries are profiled in detail?

The report provides profiles for the largest consuming and producing countries, enabling benchmarking across peers.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

1. INTRODUCTION

Report Scope and Analytical Framing

Report DescriptionResearch Methodology and the Analytical FrameworkData-Driven Decisions for Your BusinessGlossary and Product-Specific Terms2. EXECUTIVE SUMMARY

Concise View of Market Direction

Key FindingsMarket TrendsStrategic ImplicationsKey Risks and Watchpoints3. MARKET SIZE AND DEVELOPMENT PATH

Market Size, Growth and Scenario Framing

Market Size: Historical Data (2012-2025) and Forecast (2026-2035)Growth Outlook and Market Development Path to 2035Growth Driver DecompositionScenario Framework and Sensitivities4. CATEGORY SCOPE, DEFINITIONS AND BOUNDARIES

Commercial and Technical Scope

What Is Included and How the Market Is DefinedMarket Inclusion CriteriaProduct / Category DefinitionExclusions and BoundariesDistinction From Adjacent Products and Substitute Categories5. CATEGORY STRUCTURE, SEGMENTATION AND PRODUCT MATRIX

How the Market Splits Into Decision-Relevant Buckets

By Product Type / ConfigurationBy Application / End UseBy Customer / Buyer TypeBy Channel / Business Model / Technology PlatformSegment Attractiveness MatrixProduct Matrix and Segment Growth Logic6. DEMAND, CUSTOMER AND CONSUMER ARCHITECTURE

Where Demand Comes From and How It Behaves

Consumption / Demand by Country or Region: Historical Data (2012-2025) and Forecast (2026-2035)Demand by End-Use and Buyer GroupDemand by Customer / Consumer SegmentPurchase Criteria, Switching Logic and Adoption BarriersReplacement, Replenishment and Installed-Base DynamicsFuture Demand Outlook7. PRODUCTION, SUPPLY AND VALUE CHAIN

Supply Footprint, Trade and Value Capture

Production by CountryManufacturing Footprint and Supply HubsCapacity, Bottlenecks and Supply RisksValue Chain Logic and Margin PoolsRoute-to-Market and Distribution Structure8. TRADE, SOURCING AND IMPORT DEPENDENCE

Trade Flows and External Dependence

Exports by CountryImports by CountryTrade Balance and Sourcing StructureImport Dependence and Supply ResilienceStrategic Trade Corridors9. PRICING, PROMOTION AND COMMERCIAL MODEL

Price Formation and Revenue Logic

Price Levels and Price CorridorsPricing by Segment / Specification / GeographyCost Drivers and Margin LogicPromotion, Discounting and Procurement PatternsRevenue Quality and Commercial Levers10. COMPETITIVE LANDSCAPE AND PORTFOLIO POWER

Who Wins and Why

Market Structure and ConcentrationCompetitive ArchetypesSegment-by-Segment Competitive IntensityPortfolio Breadth and Product PositioningCapability MatrixStrategic Moves, Partnerships and Expansion Signals11. GEOGRAPHIC LANDSCAPE AND COUNTRY ROLES

Where Growth and Supply Concentrate

Core Demand MarketsCore Production MarketsExport HubsImport-Reliant MarketsFastest-Growing MarketsCountry Archetypes and Strategic Roles12. GROWTH PLAYBOOK AND MARKET ENTRY

Commercial Entry and Scaling Priorities

Where to PlayHow to WinBuild vs Buy vs PartnerRoute-to-Market ChoicesLocalization and Capability ThresholdsEntry Risks and Mitigation13. WHERE TO PLAY NEXT: MOST ATTRACTIVE GROWTH OPPORTUNITIES

Where the Best Expansion Logic Sits

Most Attractive Product NichesMost Attractive Customer SegmentsMost Attractive Markets for Commercial ExpansionWhite Spaces and Unsaturated OpportunitiesHigh-Margin and Underpenetrated PocketsMost Promising Product Adjacencies14. PROFILES OF MAJOR COMPANIES

Leading Players and Strategic Archetypes

Leading Manufacturers and SuppliersRegional Specialists and ChallengersProduction Footprint and Manufacturing CapacitiesProduct Portfolio and Segment FocusPricing Positioning and Indicative Price LogicChannel / Distribution StrengthStrategic Archetypes15. COUNTRY PROFILES

Detailed View of the Most Important National Markets

View detailed country profiles50 countries

15.1

United States